Literature DB >> 32916163

Unique clinicopathologic and genetic alteration features in early onset colorectal carcinoma compared with age-related colorectal carcinoma: a large cohort next generation sequence analysis.

David Escobar1, Ryan Jones1, Juehua Gao1, Leyu Sun1, Jie Liao1, Guang-Yu Yang2.   

Abstract

Colorectal carcinoma (CRC) is the third most common cancer type in the United States. While the incidence of CRC is decreasing among an older population undergoing screening, the incidence of early-onset CRC is rising. There is a growing understanding that the molecular underpinnings of colorectal carcinoma vary by age. In this study, we report the genetic alterations and clinicopathologic features of a single-institution colorectal carcinoma cohort over a 2-year period using a next-generation sequencing (NGS) approach and microsatellite stability (MS) status determined by immunohistochemical staining. Forty cases were identified in an early-onset colorectal carcinoma cohort (eCRC) defined by age <40 years, and 164 cases were identified in an age-related colorectal carcinoma cohort (arCRC) defined by age >70 years. eCRC was more often-left-sided/rectal and more likely to present high rates of lymph node positivity with metastatic disease. NGS mutational analysis revealed distinct differences between eCRC and arCRC, with eCRC being characterized by low frequency of PIK3CA mutations, elevated frequency of KRAS and CTNNB1 mutations in microsatellite instability high tumors, and very low frequency of BRAF mutations.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  CTNNB1; Clinicopathologic features; Early onset colorectal carcinoma; Genetic alterations; KRAS; NGS; PIK3CA

Mesh:

Substances:

Year:  2020        PMID: 32916163      PMCID: PMC9526519          DOI: 10.1016/j.humpath.2020.08.002

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.526


  32 in total

1.  Location of colon cancer (right-sided versus left-sided) as a prognostic factor and a predictor of benefit from cetuximab in NCIC CO.17.

Authors:  S Y Brulé; D J Jonker; C S Karapetis; C J O'Callaghan; M J Moore; R Wong; N C Tebbutt; Cr Underhill; D Yip; J R Zalcberg; D Tu; R A Goodwin
Journal:  Eur J Cancer       Date:  2015-05-12       Impact factor: 9.162

2.  Tumor suppressor Fbxw7 antagonizes WNT signaling by targeting β-catenin for degradation in pancreatic cancer.

Authors:  Jian-Xin Jiang; Cheng-Yi Sun; She Tian; Chao Yu; Mei-Yuan Chen; Hao Zhang
Journal:  Tumour Biol       Date:  2016-08-03

3.  Global patterns and trends in colorectal cancer incidence in young adults.

Authors:  Rebecca L Siegel; Lindsey A Torre; Isabelle Soerjomataram; Richard B Hayes; Freddie Bray; Thomas K Weber; Ahmedin Jemal
Journal:  Gut       Date:  2019-09-05       Impact factor: 23.059

4.  Low somatic K-ras mutation frequency in colorectal cancer diagnosed under the age of 45 years.

Authors:  Kathryn Alsop; Leeanne Mead; Letitia D Smith; Simon G Royce; Andrea A Tesoriero; Joanne P Young; Andrew Haydon; Garry Grubb; Graham G Giles; Mark A Jenkins; John L Hopper; Melissa C Southey
Journal:  Eur J Cancer       Date:  2006-06-09       Impact factor: 9.162

5.  Colorectal Cancer Incidence Patterns in the United States, 1974-2013.

Authors:  Rebecca L Siegel; Stacey A Fedewa; William F Anderson; Kimberly D Miller; Jiemin Ma; Philip S Rosenberg; Ahmedin Jemal
Journal:  J Natl Cancer Inst       Date:  2017-08-01       Impact factor: 13.506

6.  Colorectal cancer in U.S. adults younger than 50 years of age, 1998-2001.

Authors:  Temeika L Fairley; Cheryll J Cardinez; Jim Martin; Linda Alley; Carol Friedman; Brenda Edwards; Patricia Jamison
Journal:  Cancer       Date:  2006-09-01       Impact factor: 6.860

7.  Comprehensive Genomic Landscapes in Early and Later Onset Colorectal Cancer.

Authors:  Christopher H Lieu; Erica A Golemis; Ilya G Serebriiskii; Justin Newberg; Amanda Hemmerich; Caitlin Connelly; Wells A Messersmith; Cathy Eng; S Gail Eckhardt; Garrett Frampton; Matthew Cooke; Joshua E Meyer
Journal:  Clin Cancer Res       Date:  2019-06-26       Impact factor: 12.531

8.  Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer.

Authors:  Rafael G Amado; Michael Wolf; Marc Peeters; Eric Van Cutsem; Salvatore Siena; Daniel J Freeman; Todd Juan; Robert Sikorski; Sid Suggs; Robert Radinsky; Scott D Patterson; David D Chang
Journal:  J Clin Oncol       Date:  2008-03-03       Impact factor: 44.544

9.  Association of age with survival in patients with metastatic colorectal cancer: analysis from the ARCAD Clinical Trials Program.

Authors:  Christopher H Lieu; Lindsay A Renfro; Aimery de Gramont; Jeffrey P Meyers; Timothy S Maughan; Matthew T Seymour; Leonard Saltz; Richard M Goldberg; Daniel J Sargent; S Gail Eckhardt; Cathy Eng
Journal:  J Clin Oncol       Date:  2014-09-20       Impact factor: 44.544

10.  Clinical Validation of Targeted Next Generation Sequencing for Colon and Lung Cancers.

Authors:  Nicky D'Haene; Marie Le Mercier; Nancy De Nève; Oriane Blanchard; Mélanie Delaunoy; Hakim El Housni; Barbara Dessars; Pierre Heimann; Myriam Remmelink; Pieter Demetter; Sabine Tejpar; Isabelle Salmon
Journal:  PLoS One       Date:  2015-09-14       Impact factor: 3.240

View more
  1 in total

Review 1.  Recent Updates on the Significance of KRAS Mutations in Colorectal Cancer Biology.

Authors:  Loretta László; Anita Kurilla; Tamás Takács; Gyöngyi Kudlik; Kitti Koprivanacz; László Buday; Virag Vas
Journal:  Cells       Date:  2021-03-17       Impact factor: 6.600

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.